Clear answers before the next step.

SeroMark-1 is described by Nutech as a serum biomarker screening aid intended to provide structured prostate cancer risk information for doctor-guided review. Its final intended use and public claims must remain consistent with documented evidence and applicable regulatory status.

No. A screening result cannot confirm or exclude prostate cancer. Diagnosis requires an appropriate medical evaluation led by qualified healthcare professionals and may involve examination, established laboratory tests, imaging, biopsy, or other investigations.

No. SeroMark-1 should not replace PSA, clinical examination, medical history, imaging, or physician judgement. A doctor decides which information is appropriate for an individual patient.

The current website describes a screening conversation for men aged 40 to 65, including those seeking proactive risk information or with relevant risk factors. Age alone does not determine suitability, and the final criteria must be clinically and regulatorily approved.

Not necessarily. Screening is generally discussed before symptoms appear. New, persistent, or concerning symptoms should be assessed directly by a healthcare professional rather than managed through an online screening explanation.

Yes. Nutech's current approved workflow states that the blood sample is collected while the patient is fasting. Follow the preparation instructions supplied for your confirmed appointment because individual or combined-test requirements may vary.

The pathway is designed around a routine venous blood sample collected by an appropriately trained professional and handled through the approved identification, transport, and laboratory workflow.

Nutech's approved material states a four-day laboratory turnaround from sample receipt to report. Collection, shipment, doctor review, holidays, repeat quality checks, or an unsuitable sample may affect the total time for an individual appointment.

The website presents low, borderline, and elevated bands as a structured way to communicate the index. The thresholds and recommended wording must be clinically verified, and every result should be interpreted with age, history, examination findings, and other appropriate information.

No. An elevated screening result is not a cancer diagnosis. It indicates that prompt clinical review may be appropriate so a qualified professional can determine whether further evaluation is needed.

No. No screening result should be used to ignore symptoms, cancel appropriate follow-up, or assume that cancer is impossible. Continue the screening and care schedule recommended by your doctor.

Reports should be released through the approved clinical channel associated with the service. Ask who will explain the result, how to arrange follow-up, and what to do if you cannot access your report.

Not yet. The current locations page uses planning-stage coverage examples. Confirm the actual facility, appointment, operating hours, service availability, and collection instructions with Nutech before travelling.

Use the approved secure patient or clinical channel when available. Do not place detailed medical records, government identifiers, payment details, or passwords in a general website enquiry or ordinary email.

Registration may begin the account-review process, but professional and laboratory access should remain restricted until identity, credentials, organization, role, and other applicable requirements have been verified and approved.

Do not wait for a website or email response. Contact local emergency services or go to an appropriate healthcare facility immediately.